Below you can find all of Shasqi's current and previous conference submissions.
2021 - AACR - First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Advanced Solid Tumors
2021 - AACR - The CAPAC Platform Maximizes Therapeutic Benefit and Reduces Systemic Cytotoxic Exposure in Small and Large Animals
2020 - SITC - First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Advanced Solid Tumors
2020 - SITC - SQ3370 is a novel approach that decreases adverse drug exposure and achieves robust injected and non-injected anti-tumor responses
2020 - MSTS - SQ3370, a Novel Technology to Locally Capture and Activate Cytotoxic Drugs, Produces Systemic Responses in Injected and Non-injected Lesions via Immune Activation.
2020 - CTOS - First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Soft Tissue Sarcomas and Other Advanced Solid Tumors
2020 - CTOS - SQ3370 Activates Cytotoxic Drugs at Tumor via Click Chemistry and Produces Sustained Responses in Injected and Non-injected Lesions in Preclinical Models
2020 - AACR - SQ3370, a Local Activation Therapy (LAT) of Cytotoxic Agents, Produces Sustained Responses in Target and Distal Lesions via Immune Activation.
2019 - ASCO - SQ3370: Biomaterial-dependent local drug activation of systemic cytotoxic prodrugs
2019 - AACR - SQ3370 enhances the safety of chemotherapeutics via local activation therapy
2018 - ASCO - Local drug activation: safer cytotoxics for local tumors